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1. Introduction 
Iopamidol is radio opaque Nonionic contrast media used parenterally for diagnostic purpose. Solubility of 
iopamidol is very limited in water. Various Marketed formulations suffer the problem of crystallization of Iopamidol; such 
crystallization is very crucial as it will vary the dose and also effective drug in the solubilized form is minimized. After 
multiple use of Iopamidol injection Vials the iopamidol tends to get crystallize. For this reason many marketed formulations 
gives indication of “Crystals may form in the solution but are readily redissolved by immersing the container in hot water 
and gently shaking it”. Such redissolution of crystals is a hectic procedure for a Physician. Many times it may take several 
minutes to get iopamidol redissolved.[1] 
 Such context of flaws in predecessor approaches in formulation of Iopamidol Injection, scarcity of research work, 
asked for extensive research work. The overall scenario triggered to aim the development of stable, Noncrystallizable 
Iopamidol Injection to assist Physician in rapid clinical Intervention. And also to achieve dose uniformity in each dozing, 
various adjutants/cosolvents were studied to formulate a stable, Noncrystallizable Iopamidol Injection.[2-5] 
 
Figure 1: Structure of Iopamidol 
Abstract 
Parenteral administration offers many advantages over therapy, given 
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2. Experimental work 
2.1 formulation of iopamidol injection: 
It was desirable to adept the formulation, technique in formulation step to avoid microbial contamination, which is 
possible to various steps. 
Table 1: Formulation of iopamidol injection as a control batch 
Sr. No. Ingredients Use Quantity Taken 
1 Iopamidol Active ingredient 1530.85 g 
2 Trometamine Antioxidant 2.5g 
3 Calcium disodium EDTA Chelating agent 1.0g 
4 Water for injection Vehicle q.s. 
5 Buffer(Dil. HCL) To maintain pH q.s. 
Iopamidol injection 50 ml vial (Batch of 50 vials) 
The total volume formulated 2500 ml. The concentration of Iopamidol drug was 612.34mg/ml. 
Procedure:  
Heat the half quantity of water for injection about 80-90° C,  & add accurately weigh iopamidol and stir it for 5-10 
min, then add tromethamine and calcium disodium EDTA and stirr gently, slowly they are soluble in water for injection 
then add little amount of water for injection and stirr, the above ingredient are completely soluble in water for injection. 
Add remaining amount of water for injection to make up the volumn, adjust the pH with dilute HCl about 6.5-7.5. fill the 
solution in the vial aseptically and autoclave it at temperature of  about 121° C for 45 min. 
 
Table 2:  Formulation of iopamidol injection by using cosolvant and adjuvants 
S. No. Ingredient Use F1 F2 F3 F4 F5 
1 Iopamidol Active ingredient 306.170g 306.170g 306.170g 306.170g 306.170g 
2 Tromethamine Antioxidant 0.5g 0.5g 0.5g 0.5g 0.5g 
3 Calcium Disodium EDTA Chelating agent 0.2g 0.2g 0.2g 0.2g 0.2g 
4 PG (1.0%) Cosolvant 5.0 ml - - - - 
5 PG (2.0%) Cosolvant - 10.0ml - - - 
6 PVP Adjuvant - - 0.05 g - - 
7 Urea Adjuvant - - - 0.5g - 
8 Mannitol Adjuvant - - - - 0.5 g 
9 Water For Injection Vehical q.s. q.s. q.s. q.s. q.s. 
10 Buffer (Dil.HCl) To maintain pH q.s. q.s. q.s. q.s. q.s 
Iopamidol injection 50 ml vial (Batch of 10 vials) 
F: Formulation; PG: Propylene Glycol; PVP: Polyvinylpyrrolidon; Dil.HCl: Dilute Hydrochloric Acid 
2.2 Packaging  
Above formulation was prepared aseptically and packed in 50 ml vial by using type I glass container with rubber 
closure. 
2.3 Stability and Storage: 
Table 3: Stability and Storage 
Sr. No. Formulation 
Storage Condition (1
ST
 Day) 
2-8° C Room Temperature 30-35° C 35-40° C 
1 CONTROL SAMPLE STABLE STABLE STABLE STABLE 
2 F1 STABLE STABLE STABLE STABLE 
3 F2 STABLE STABLE STABLE STABLE 
4 F3 STABLE STABLE STABLE STABLE 
5 F4 STABLE STABLE STABLE STABLE 
6 F5 STABLE STABLE STABLE STABLE 
F: Formulation 
Formulation of iopamidol injection was formulated and kept for stability study for 60 days in different temperature 
along with its control batch sample. 
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2.4 Evaluations of injection batches 
A) Solubility Test 
B) pH  
C) Assay  
Procedure:  
Transfer about 300 mg of iopamidol, accurately weighed to a glass stopper. 125 ml conical flask add 40 ml of 
1.25M sodium hydro oxide and 1.0 g of zinc powder, connect the flask to a reflux condenser, and reflux the mixture for 30 
min. cool the flask to room temperature, rinse the condenser with 20 ml of distilled water, disconnect the flask from the 
condenser and filter the mixture. Rinse the flask and filter thoroughly adding rinsing to the filtrate. Add 5 ml of glacial 
acetic acid and titrate with 0.1 N silver nitrate to determining the end point by potentiometrically.[6] 
Each ml of 0.1 N silver nitrate is equivalent to 25.90 mg of iopamidol. 
D) Official test of iopamidol as per USP   
Free aromatic amine test: 
Transfer 500 mg to a 25 ml volumetric flask, and add 20.0 ml of distilled water heating on a water bath, if 
necessary to affect solution .to a second 25 ml volumetric flask transfer 18.4 ml of distilled water and 1.6 ml of standard 
solution prepared by dissolving a suitable quantity of USP iopamidol related compound.  
A RS in water and diluting with water to obtain a concentration of 62.5 µg/ml. to a third 25 ml volumetric flask 
add 20 ml of distilled water to provide a blank. Treat each flask as follows. Place the flask in ice bath, protected form light 
for 5 min (note – in conducting the following steps, keep the flask in the ice bath and protected from light as much as 
possible until all the reagent have been added ) 
Add slowly 1.0 ml of HCL, mix and allow to stand for 5 min. add 1.0 ml of ammonium sulfa mate solution (3 in 
25) shake and allow to stand for 5 min (caution-considerable pressure is produce) add 1.0 ml of N-(1-Naphthyl) 
ethylenediamine dihydrochloride solution (1 in 1000) and mix. remove the flask from ice bath and allow to stand in water 
bath at about 25 for 10 min. dilute with water to volume mix and without delay (about 5 min from final dilution), 
concomitantly determine the absorbance of the solution from the substance under test and the standard solution in 1- cm 
cells at a wavelength of maximum absorbance at about 500 nm with a suitable spectrophotometer, against the prepared 
blank. The absorbance of the solution from iopamidol is not greater than that of the standard solution (0.02 %).[6] 
Free IODINE 
Transfer 2.0 g to a stopered, 50.0 ml centrifuge tube add sufficient water to dissolve, heating on a water bath, if 
necessary to effect solution, and dilute with water to 25.0 ml. add 5.0 ml of toluene and 5.0 ml of 2N sulfuric acid. Shake 
well and centrifuge the toluene layer shows no red color. [7] 
Limit of free iodide:  
Transfer about 6 g accurately weight to a suitable container, dissolved in 50 ml of water and add 2.0 ml 0.001 M 
potassium iodide. Titrate with 0.001 N silver nitrate and determining the end point by potentiometrically using silver 
indicator electrode and an appropriate reference electrode. Perform a blank determination and make ant necessary 
correction each ml of 0.001 N silver nitrate is equivalent to 126.9 µg of iodide. Not more than 0.001 % is found.[7] 
Thin Layer Chromatography 
Prepare a filter and degassed a mixture of water and methanol (3:1). Mobile Phase use various mixture of solution 
A and solution B as directed under chromatographic system. 
System suitability solution  
Transfer 10.0 mg of USP iopamidol related compound B RS and 10.0 mg of USP iopamidol RS into 1000.0ml 
volumetric flask dissolved in and dilute with water volume and mix.  
Test solution  
Transfer about 1.0 g of iopamidol accurately weighed to a 100.0 ml volumetric flask, add water to volume and 
mix.  
Chromatographic system 
The liquid chromatography is equipped with 240 nm detector and 46 mm x 25- cm stainless still that contain 5 µm 
packing L1, the column temperature maintained at 35 c, and flow rate is about 1.5 ml /min. the chromatograph is 
programmed to provide variable mixture of solution A and B . the percentage of solution B being 8 % at the time of 
injection and is held at that % for 6 min, then increase linearly to 35 % at 18 min, after which it is changed to increase 
linearly to 92 % at 30 min. maintain at that % for 4 min and decrease linearly to 8 % at 36 min where it is held to the end of 
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run at 40 min. chromatograph the suitability solution and record the peak response as directed under procedure the 
resolution R between the iopamidol related compound B and iopamidol is not less than 7. [8] 
Procedure 
Separately inject equal volumn (about 20.0 ml) of the system suitability solution and test solution into a 
chromatogram and measure the area of peak response calculate the % of each related compound in the portion of iopamidol 
taken by the formula 
                                                     0.10 (ri/rs) 
Where , 
ri = peak response for individual related compound obtained from test solution 
rs = peak response for iopamidol related compound B obtained from system suitability solution. 
The sum of all related compound does not exceed 0.25 %. 
2.5 Animal Study 
Toxicity test: 
Rabbit test 
Take three healthy rabbits of same species having weight not less than 1.5 kg. then inject iopamidol injection of 
about 5.7 ml to the marginal ear vein of rabbit and keep the rabbit under observation for 5 days. 
Mice test  
Take 10 healthy mice of same species having weight not less than 15 g then inject about 0.1 ml of iopamidol 
injection to the mice and keep it for observation for 5 days.  
2.6 Evaluation of formulation for stability[9-11] 
For a product to be stable, it should be within the limit of monograph of specification, regarding its identity, 
strength, quality and purity throughout its shelf life.  
The purpose of stability testing is to provide evidence on how the quality of drug substance or product varies with 
time under the influence of variety of the environmental factor like temperature, humidity, light etc. thus enabling 
recommendation of storage condition and to establish shelf life. 
In stress testing of a drug or a product it is exposed to elevated temperature and humidity, over a period of time, 
called the  " accelerated stability condition ' and the data obtained predicts stability, storage condition and shelf life of drug 
substance or product when kept under specified storage condition.  
The prepared formulation was subjected to accelerated stability study at different temperature like 2-8°C, room 
temperature (27°C), 30-35°c & 35-40°C for a period ranging from 1
st
 day to 60 days. 
The formulation was tested for  
a) Particulate matter 
b) pH 
c) % content 
2.7 Drug-Excipient Interaction Study 
 After the selection of emulsifiers all the formulation ingredients were subjected to drug excipient interaction 
studies to determine any possible interaction with drug molecule. The interaction study was carried by using Fourier 
Transform Infra red spectroscopy (FTIR). 
2.7.1 Fourier Transform Infrared Spectroscopy (FT-IR) 
The FT-IR spectra were obtained using FT-IR spectrometer (Shimadzu).The samples (Iopamidol /Excipient) were 
previously ground and mixed thoroughly with potassium bromide, an infrared transparent matrix in 1:5  (sample : KBr) 
ratio, respectively. The KBr discs were prepared by compressing the powders at a pressure of 5 tons for 5 min in a hydraulic 
press. Thirty scans were obtained at a resolution of 2 cm
1
 from 4500 to 400 cm
1
.
 
  
2.8 Microscopic study of formulation 
Microscopic evaluation of marketed formulation (crystals) in the formulation was performed using motic Digital 
Microscope using Plus 2.0 software in department of Pharmaceutical sciences, R. T. M. Nagpur University under the 
guidance of Dr. P. R. Itankar to characterize the crystal structure of the crystals of iopamidol formed in the marketed 
preparation. 
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3. Results and Discussion 
3.1 Test Result 
Table 4: Solubility 
SR. NO. Formulation Solubility 
1 Control batch soluble 
2 F1 soluble 
3 F2 soluble 
4 F3 soluble 
5 F4 soluble 
6 F5 soluble 
For the above table it is clear that iopamidol shows high solubility in polar solvents like water. And in formulation 
using cosolvant and adjuvants they are soluble in water. 
Table 5: pH of formulatiion 
Sr. No. Formulation pH (6.5-7.5) 
1 Control batch 7.4 
2 F1 6.8 
3 F2 7.2 
4 F3 6.8 
5 F4 7.4 
6 F5 6.8 
pH of all formulation was found in the range of 6.5-7.5. Ideally, the formulation should have possessed the pH in 
range 6.5-7.5 so as to minimize discomfort and irritation to the body. No modification of pH was attempted for the 
experimental formulation for the reason of solubility and stability. 
Figure 2: pH values of various formulation of Iopamidol Injection 
 
Table 6: ASSAY 
Sr. No. Formulation Assay (95-105%) 
1 Control batch 97.68% 
2 F1 96.42% 
3 F2 99.37% 
4 F3 98.95% 
5 F4 98.52% 
6 F5 96.16% 
From the table it was clear that the % purity of iopamidol injection is within the range. 
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Figure 3: Assay values of various formulation of iopamidol Injection 
 
 
Table 7: Assay of marketed product containing crystals 
Sr. No. Formulation 
Assay 
Clear Solution Crystal Assay 
1 Uniray Product (Iopamidol Injection) 
81.04% 126.81% 
79.36% 122.19% 
 
From the above it was clear that in the crystal formation product, the clear solution have less percentage purity and 
the crystal has more % purity hence it is concluded that the crystal are produce to that of active ingredient i.e. Iopamidol & 
the pH of the product (clear solution)-7.2 and pH (crystal solution)-7.4, i.e. within limit.   
 
Official Test Result 
Table 8: Free aromatic amine test 
Sr. No. Formulation Test Result 
1 Control batch complies 
2 F1 complies 
3 F2 complies 
4 F3 complies 
5 F4 complies 
6 F5 complies 
The absorbance of the solution from the iopamidol is not grether than that of standard solution. Hence all 
formulation complies the test. 
Table 9: Free iodine test 
Sr. No. Formulation Test Result 
1 Control batch complies 
2 F1 complies 
3 F2 complies 
4 F3 complies 
5 F4 complies 
6 F5 complies 
As there was no pink or red colour in the toluene layer hence the above formulation complies the test. 
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Thin Layer Chromatography 
Table 10: Rf values of formulation 
Sr. No. Formulation Rf Value (Less Than 1) 
1 Control batch 0.86 
2 F1 0.85 
3 F2 0.95 
4 F3 0.96 
5 F4 0.97 
6 F5 0.92 
As the Retention factor was less than 1 it indicates that the above formulation do not content impurities.  
 
3.2 Animal Study 
Table 11: Results of toxicity study of formulation 
Sr. No. Formulation 
Toxicity Test 
Rabbit Mice 
1 Control batch No toxicity found No toxicity found 
2 F1 No toxicity found No toxicity found 
3 F2 No toxicity found No toxicity found 
4 F3 No toxicity found No toxicity found 
5 F4 No toxicity found No toxicity found 
6 F5 No toxicity found No toxicity found 
As there was no reaction in 10 days of observation so, the above formulation had no toxicological effect in animal. 
hence passes the test. 
3.3 Stability Results 
Table 12: Particulate matter 
Sr. No. Formulation 
Particulate Matter 
1
st
 day 60
th
 day 
1 Control batch Transparent Transparent 
2 F1 Transparent Transparent 
3 F2 Transparent Transparent 
4 F3 Transparent Transparent 
5 F4 Transparent Transparent 
6 F5 Transparent Transparent 
 
Table 13: Assay 
Sr. No. Formulation 
Assay 
1
st
 Day 60
th
 Day 
1 Control batch 97.68% 96.78% 
2 F1 96.42% 96.35% 
3 F2 99.37% 99.27% 
4 F3 98.95% 98.57% 
5 F4 98.52% 98.42% 
6 F5 96.16% 96.12% 
 
Table 14: pH 
Sr. No. Formulation 
pH 
1
st
 Day 60
th
 Day 
1 Control batch 7.4 7.3 
2 F1 6.8 6.8 
3 F2 7.2 7.2 
4 F3 6.8 6.7 
5 F4 7.4 7.2 
6 F5 6.8 6.7 
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3.4 Drug excipient interaction study 
The interaction study was carried by using Fourier Transform Infra red spectroscopy (FTIR). 
Compatibility study by Fourier transforms infrared spectroscopy (FT-IR) 
Shown in figure, FTIR are the absorption Spectrum of A) Iopamidol B) 1:1 Physical mixture of Iopamidol and 
propylene glycol, C) 1:1 Physical mixture of Iopamidol and urea, D) 1:1 Physical mixture of Iopamidol and PVP, E) 1:1 
Physical mixture of Iopamidol and Mannitol, F) 1:1 Physical mixture of Iopamidol and mixture of all excipient. 
In order to characterize possible interactions between the drug and the excipient, infrared spectra were recorded. Infrared 
spectrum of Iopamidol is characterized by the aromatic-0H in plane bend at 1352 cm
-1
, COOH group stretching at 1535 cm
-
1 
, aromatic nitro compounds at 1460 cm
-1
. 
Comparing the spectra of Physical mixtures of various excipient individually and finally with mixture of all 
excipient with that of Iopamidol gives idea about possible interaction. No any significant shift in absorption bands (which 
are characteristics of Iopamidol) was observed. Therefore it can be ascertained that no significant interaction in the 
Iopamidol and excipient exists. 
Figure 4A – FTIR spectrum of Iopamidol drug 
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Figure 4B – FTIR spectrum of iopamidol+ propylene glycol 
 
 
Figure –4 C: FTIR spectrum of iopamidol +urea 
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Figure – 4D FTIR spectrums of Iopamidol + PVP 
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Figure – 4E:  FTIR spectrum of Iopamidol + Mannitol 
 
 
Figure – 4F: FTIR spectrum of Iopamidol + all mixture 
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3.5 Microscopic study of formulation. 
Microscopic evaluation of marketed formulation (crystals) in the formulation was performed using motic Digital 
Microscope using Plus 2.0 software in Department of Pharmaceutical sciences, R. T. M. Nagpur University under the 
guidance of Dr. P. R. Itankar to characterize the crystal structure of the crystals of iopamidol formed in the marketed 
preparation. 
Orthorhombic and Rhombic crystals were found in the formulation which are dispersed and are of size 4-5 mm in 
size. Moreover crystal settles at the bottom and forms a stuff cake which is not dispersed easily. 
On the contrary, batches prepared using various adjutants and cosolvents viz. F1, F2, F3, F4, F5 were clear and has 
total absence of crystals. 
 
Figure 5: Shown in the figure are the Photographic of marketed formulation (UNIRAY) having crystals settled at 
bottom. 
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Figure 6: Shown in the figure are the motic images of crystals of iopamidol in marketed preparation. 
 
 
Figure 7: Shown in the figure are the Photographic of optimized formulation (F2) having clear solution without any 
crystals settled at bottom. 
 
4. Summary & conclusion 
The Parenteral formulation of Iopamidol using cosolvents and adjuants provide a better alternative for increasing 
stability of formulation.  
Iopamidol is a radio opaque nonionic contrast media, having limited solubility in water. 
In the present work the parenteral formulation of Iopamidol was formulated by using various cosolvents and 
solubility enhancers. Use of cosolvents and solubility enhancers provide a unique possibility for increasing solubility of 
Iopamidol and thereby decreaseing its recrystalization in the formulation  
Cosolvents and solubility enhancers exhibit some characteristic feature when used in formulation. It was observed 
during study that various cosolvents and solubility enhancers increases the solubility of Iopamidol. Parenteral formulation 
batches composed of active pharmaceutical ingredient (Iopamidol), antioxidant (Tromethamine), chelating agent(Calcium 
disodium EDTA), cosolvents, adjutants were prepared and evaluated. In the present study all excipients which are 
extensively used in the pharmaceutical industry and widely accepted were selected.[12-14] 
Formulation batches F2 and F3 were selected as optimum batches which have shown the least crystallization 
of Iopamidol.  
Stability studies of formulation at different temperatures (2-8 
0
C, Room temperature, 30-35
0
C and 35-40
0
C for 
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two months showed no significant effect on physical properties and assay. 
No subtle variation in infrared absorption patterns FTIR study, it can be concluded that no significant drug –
excipients interaction exists. 
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